Newsroom
For media inquiries, please contact 340B Health Senior Director of Communications David Glendinning at david.glendinning@340bhealth.org or 202-536-2289.
-
STATEMENT ON UCB RESTRICTING 340B DISCOUNTS THROUGH COMMUNITY-BASED PHARMACIES
-
As Big Pharma and Hospitals Battle Over Drug Discounts, Patients Miss Out on Millions in Benefits
-
STATEMENT ON FEDERAL COURT OPINION IN NOVARTIS AND UNITED THERAPEUTICS 340B COMMUNITY PHARMACY LAWSUITS
-
STATEMENT ON FEDERAL COURT OPINION IN SANOFI AND NOVO NORDISK 340B COMMUNITY PHARMACY LAWSUITS
-
REPORT: 340B HOSPITALS ARE DIRECTING SAVINGS TOWARD THEIR COMMUNITIES’ UNIQUE NEEDS
-
STATEMENT ON MEDICARE PAYMENT CUTS TO 340B HOSPITALS IN 2022
-
STATEMENT ON FEDERAL COURT OPINION IN 340B COMMUNITY PHARMACY LAWSUIT
-
340B HEALTH BOARD ELECTS TWO NEW MEMBERS
-
How drugmaker restrictions on 340B discounts affect hospital pharmacies: 5 systems weigh in
-
STATEMENT ON FEDERAL 340B ENFORCEMENT ACTIONS AGAINST BOEHRINGER INGELHEIM
-
SIX DRUG COMPANIES REFERRED FOR PENALTIES FOR CONTINUED VIOLATIONS OF FEDERAL LAW ON 340B PRICING
-
DIABETES DRUGS HEAVILY IMPACTED BY DRUGMAKERS’ 340B POLICIES